Skip to main content

Our Pipeline

We think differently and innovate relentlessly in pursuit of elegant solutions to the most difficult challenges facing patients. Our next-generation therapeutics are transforming patient care today.

Let science lead the way

Our cutting-edge science serves as the foundation for a deep and diverse pipeline of small-molecule and protein therapeutics focused on significant unmet medical needs – a pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes.

Omeros has retained exclusive control of worldwide commercial rights for all products, product candidates, and programs (except zaltenibart).

Therapeutic Area
Phase
Antibody
Small Molecule

Complement Franchise

Narsoplimab

([OMS721],MASP-2 inhibitor,lectin pathway)

Stem Cell Transplant-Associated TMA (TA-TMA)

COVID-19 and ARDS

Zaltenibart

([OMS906],MASP-3 inhibitor,alternative pathway)

Novo Nordisk is developing zaltenibart under an asset acquisition and licensing agreement in PNH. Novo Nordisk is also pursuing zaltenibart in other rare hematologic and renal disorders.

OMS1029

(MASP-2 inhibitor)

Long-Acting 2nd Generation Antibody Targeting Lectin Pathway Disorders

MASP‑2, MASP‑3

Disorders of the Lectin and Alternative Pathways of Complement

Addiction

OMS527

(PDE7 inhibitor)

Addictions and Compulsive Disorders; Movement Disorders

Oncology

OncotoX

Cancer

Cancer Vaccines

Cancer

Discovery Platform Technologies

GPCR Platform

Immunologic, CNS, Metabolic, CV, Musculoskeletal & Other Disorders